Day One Biopharmaceuticals (DAWN) to Release Quarterly Earnings on Tuesday

Day One Biopharmaceuticals (NASDAQ:DAWN) will likely be announcing its earnings results after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Day One Biopharmaceuticals Price Performance

NASDAQ DAWN opened at $12.43 on Monday. The company has a market cap of $1.25 billion, a P/E ratio of -12.07 and a beta of -1.46. The stock has a 50-day moving average of $12.37 and a two-hundred day moving average of $13.48. Day One Biopharmaceuticals has a 1-year low of $11.13 and a 1-year high of $18.07.

Analyst Ratings Changes

DAWN has been the subject of a number of research reports. Bank of America dropped their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. The Goldman Sachs Group decreased their target price on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a report on Monday, February 10th. Finally, Needham & Company LLC reissued a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $35.71.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the transaction, the general counsel now directly owns 39,602 shares in the company, valued at $473,639.92. This represents a 10.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total transaction of $399,300.00. Following the sale, the insider now directly owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. The trade was a 2.82 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 51,064 shares of company stock valued at $651,225. Insiders own 8.40% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.